|
1
|
Wakeam E, Acuna SA, Leighl NB, Giuliani
ME, Finlayson SRG, Varghese TK and Darling GE: Surgery versus
chemotherapy and radiotherapy for early and locally advanced small
cell lung cancer: A propensity-matched analysis of survival. Lung
Cancer. 109:78–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lopez-Pastorini A, Riedel R, Koryllos A,
Beckers F, Ludwig C and Stoelben E: The impact of preoperative
elevated serum C-reactive protein on postoperative morbidity and
mortality after anatomic resection for lung cancer. Lung Cancer.
109:68–73. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu L, Leng D, Cun D, Foged C and Yang M:
Advances in combination therapy of lung cancer: Rationales,
delivery technologies and dosage regimens. J Control Release.
260:78–91. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen C, Huang L, Zhang G, Li Y, Li L, Bai
X, Liu W, Wang H and Li J: STK33 potentiates the malignancy of
hypopharyngeal squamous carcinoma: Possible relation to calcium.
Cancer Biol Ther. 17:976–984. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Azoitei N, Hoffmann CM, Ellegast JM, Ball
CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, et
al: Targeting of KRAS mutant tumors by HSP90 inhibitors involves
degradation of STK33. J Exp Med. 209:697–711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang P, Cheng H, Wu J, Yan A and Zhang L:
STK33 plays an important positive role in the development of human
large cell lung cancers with variable metastatic potential. Acta
Biochim Biophys Sin (Shanghai). 47:214–223. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brauksiepe B, Baumgarten L, Reuss S and
Schmidt ER: Co-localization of serine/threonine kinase 33 (Stk33)
and vimentin in the hypothalamus. Cell Tissue Res. 355:189–199.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Milenic DE, Baidoo KE, Kim YS, Barkley R
and Brechbiel MW: Targeted α-particle radiation therapy of
HER1-positive disseminated intraperitoneal disease: An
investigation of the human anti-EGFR monoclonal antibody,
panitumumab. Transl Oncol. 10:535–545. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Groner B and von Manstein V: Jak Stat
signaling and cancer: Opportunities, benefits and side effects of
targeted inhibition. Mol Cell Endocrinol. 451:1–14. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu Y, Bassoff N, Reinshagen C, Bhere D,
Nowicki MO, Lawler SE, Roux J and Shah K: Bi-specific molecule
against EGFR and death receptors simultaneously targets
proliferation and death pathways in tumors. Sci Rep. 7:26022017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen H, Xing C, Cui K and Li Y, Zhang J,
Du R, Zhang X and Li Y: MicroRNA-30a attenuates mutant KRAS-driven
colorectal tumorigenesis via direct suppression of ME1. Cell Death
Differ. 24:1253–1262. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim SY, Menzies AM and Rizos H: Mechanisms
and strategies to overcome resistance to molecularly targeted
therapy for melanoma. Cancer. 123:(S11). 2118–2129. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye H, Shao M, Shi X, Wu L, Xu B, Qu Q and
Qu J: Predictive assessment in pharmacogenetics of glutathione
S-transferases genes on efficacy of platinum-based chemotherapy in
non-small cell lung cancer patients. Sci Rep. 7:26702017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brace PT, Tezera LB, Bielecka MK, Mellows
T, Garay D, Tian S, Rand L, Green J, Jogai S, Steele AJ, et al:
Mycobacterium tuberculosis subverts negative regulatory pathways in
human macrophages to drive immunopathology. PLoS Pathog.
13:e10063672017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reuss S, Brauksiepe B, Disque-Kaiser U and
Olivier T: Serine/threonine-kinase 33 (Stk33) - Component of the
neuroendocrine network? Brain Res. 1655:152–160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang L, Chen C, Zhang G, Ju Y, Zhang J,
Wang H and Li J: STK33 overexpression in hypopharyngeal squamous
cell carcinoma: Possible role in tumorigenesis. BMC Cancer.
15:132015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scholl C, Fröhling S, Dunn IF, Schinzel
AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S,
et al: Synthetic lethal interaction between oncogenic KRAS
dependency and STK33 suppression in human cancer cells. Cell.
137:821–834. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mujica AO, Hankeln T and Schmidt ER: A
novel serine/threonine kinase gene, STK33, on human chromosome
11p15.3. Gene. 280:175–181. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang T, Song B, Zhang J, Yang GS, Zhang H,
Yu WF, Wu MC, Lu JH and Shen F: STK33 promotes hepatocellular
carcinoma through binding to c-Myc. Gut. 65:124–133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Babij C, Zhang Y, Kurzeja RJ, Munzli A,
Shehabeldin A, Fernando M, Quon K, Kassner PD, Ruefli-Brasse AA,
Watson VJ, et al: STK33 kinase activity is nonessential in
KRAS-dependent cancer cells. Cancer Res. 71:5818–5826. 2011.
View Article : Google Scholar : PubMed/NCBI
|
